Level 1 evidence from the MAF Test® analyses of the NSABP-B34 landmark clinical trial confirmed clinical utility of the MAF Test® for selection of early-stage breast cancer patients that benefit from adjuvant clodronate treatment to prevent metastasis.
Data published in Journal of National Cancer Institute, Cancer Spectrum.
MAF negative status of patients who were treated with clodronate in the adjuvant setting was predictive of significantly improved disease-free survival (primary endpoint) and overall survival (key secondary endpoint).
Results confirm the company’s previous data (AZURE trial analyses) on its proprietary MAF Test® published in Lancet Oncology in 2018.
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to offer pioneering solutions to unresolved medical needs in cancer and other diseases related to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).